Secondary iron overload.
暂无分享,去创建一个
[1] R. Hider,et al. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. , 2001, Bioorganic & medicinal chemistry.
[2] Z. Cabantchik,et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. , 2001, Blood.
[3] E. Vichinsky. Consensus document for transfusion-related iron overload. , 2001, Seminars in hematology.
[4] N. Olivieri,et al. Progression of iron overload in sickle cell disease. , 2001, Seminars in hematology.
[5] R. Galanello. Iron chelation: new therapies. , 2001, Seminars in hematology.
[6] S. Sheth,et al. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. , 2001, Seminars in hematology.
[7] S. Ballas. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. , 2001, Seminars in hematology.
[8] K. Ohene‐Frempong. Indications for red cell transfusion in sickle cell disease. , 2001, Seminars in hematology.
[9] R. Fischer,et al. Factors Influencing Effectiveness of Deferiprone in a Thalassaemia major Clinical Setting , 2001, Acta Haematologica.
[10] R. Fischer,et al. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. , 2000, Transfusion science.
[11] R. Lindeman,et al. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). , 2000, Transfusion science.
[12] B. Wonke,et al. Combined oral and parenteral iron chelation in beta thalassaemia major. , 2000, The Medical journal of Malaysia.
[13] M. Kami,et al. Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.
[14] D. Weatherall,et al. Oral iron chelation therapy for thalassaemia: an uncertain scene. Annotation , 2000 .
[15] D. Weatherall,et al. Oral iron chelation therapy for thalassaemia: an uncertain scene , 2000, British journal of haematology.
[16] A. Hoffbrand,et al. Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.
[17] P. Harmatz,et al. Severity of Iron Overload in Patients with Sickle Cell Disease Receiving Chronic Red Blood Cell Transfusion Therapy , 2000, Blood.
[18] Matthew Darlison,et al. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.
[19] R. Fischer,et al. Serum ferritin iron in iron overload and liver damage: correlation to body iron stores and diagnostic relevance. , 2000, The Journal of laboratory and clinical medicine.
[20] G. Aprili,et al. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. , 2000, Blood.
[21] V. Farina,et al. Longitudinal assessment of cardiac status by echocardiographic evaluation of left ventricular diastolic function in thalassaemic children. , 2000, Acta paediatrica.
[22] J. Porter,et al. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .
[23] Vullo,et al. Safety profile of the oral iron chelator deferiprone: a multicentre study , 2000, British journal of haematology.
[24] J. Porter,et al. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. , 2000, Blood.
[25] E. Vichinsky,et al. Transfusion practice for patients with sickle cell disease. , 1999, Current opinion in hematology.
[26] L. Bonetta. Canadian fight over thalassemia drug worsens , 1999, Nature Medicine.
[27] N. Çetingül,et al. Sequential Use of Deferiprone and Desferrioxamine in Primary School Children with Thalassaemia major in Turkey , 1999, Acta Haematologica.
[28] N. Olivieri. The β-Thalassemias , 1999 .
[29] H. Bonkovsky,et al. Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. , 1999, Radiology.
[30] R. Fischer,et al. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry , 1999, American journal of hematology.
[31] T. Einarson,et al. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1) , 1999, European Journal of Clinical Pharmacology.
[32] N. Olivieri. The beta-thalassemias. , 1999, The New England journal of medicine.
[33] G. Piatti,et al. Beta-thalassemia and pulmonary function. , 1999, Haematologica.
[34] Wright,et al. Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.
[35] L. Bonetta. Inquiry into clinical trial scandal at Canadian research hospital , 1998, Nature Medicine.
[36] K. Fleming,et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.
[37] R. Hebbel,et al. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. , 1998, Blood.
[38] G. Link,et al. Pathophysiology of Iron Overload a , 1998, Annals of the New York Academy of Sciences.
[39] A. Piga,et al. A Multi‐Center Safety Trial of the Oral Iron Chelator Deferiprone , 1998, Annals of the New York Academy of Sciences.
[40] G. Link,et al. Iron Chelators for Thalassaemia , 1998, British journal of haematology.
[41] C. Howes,et al. A Trial to Investigate the Relationship between DFO Pharmacokinetics and Metabolism and DFO‐Related Toxicity , 1998, Annals of the New York Academy of Sciences.
[42] M. Cappellini,et al. Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.
[43] A. Hirt,et al. Liver iron and fibrosis during long‐term treatment with deferiprone in Swiss thalassaemic patients , 1998, British journal of haematology.
[44] G. Aprili,et al. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. , 1998, Haematologica.
[45] A. Hoffbrand,et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. , 1998, Blood.
[46] P. Mazza,et al. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. , 1998, Haematologica.
[47] A. Giovagnoni,et al. Limitations of magnetic resonance imaging in measurement of hepatic iron. , 1997, Blood.
[48] Z. Du,et al. Pulmonary hypertension in patients with thalassemia major. , 1997, American heart journal.
[49] R. Hider,et al. Inhibition of iron-containing metalloenzymes by 3-hydroxypyridin-4-one chelators , 1997 .
[50] A. Rosman,et al. Serum Ferritin Iron, a New Test, Measures Human Body Iron Stores Unconfounded by Inflammation , 1997, Stem cells.
[51] P. Milgram,et al. Chelation and mobilization of cellular iron by different classes of chelators. , 1997, Molecular pharmacology.
[52] P. Alberti,et al. Desferrioxamine ototoxicity in an adult transfusion-dependent population. , 1997, The Journal of otolaryngology.
[53] R. Hider,et al. Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[54] M. Sacco,et al. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone) , 1997, British journal of haematology.
[55] G. Brittenham,et al. Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.
[56] C. Cooper,et al. The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase* , 1996, The Journal of Biological Chemistry.
[57] R. Abeysinghe,et al. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. , 1996, Blood.
[58] W. Y. Wang,et al. Lungs in thalassaemia major patients receiving regular transfusion. , 1996, The European respiratory journal.
[59] G. Koren,et al. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. , 1996, International journal of clinical pharmacology and therapeutics.
[60] C. Cooper,et al. The Environment of the Lipoxygenase Iron Binding Site Explored with Novel Hydroxypyridinone Iron Chelators (*) , 1996, The Journal of Biological Chemistry.
[61] D. Häussinger,et al. Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.
[62] A. Hoffbrand. Oral iron chelation. , 1996, Seminars in hematology.
[63] A. Piga,et al. Results of long-term iron-chelating therapy. , 1996, Acta haematologica.
[64] A. Hoffbrand,et al. Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators , 1995, British journal of haematology.
[65] S. Andò,et al. Multicentre study on prevalence of endocrine complications in thalassaemia major , 1995, Clinical endocrinology.
[66] D. Templeton,et al. Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. , 1995, Biochimica et biophysica acta.
[67] G. Koren,et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.
[68] D. Nathan. An orally active iron chelator. , 1995, The New England journal of medicine.
[69] G. Lucarelli,et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies , 1995, British journal of haematology.
[70] F. Cerutti,et al. Insulin resistance and hyperinsulinemia in homozygous β-thalassemia☆ , 1995 .
[71] A. Hoffbrand,et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload , 1995, British journal of haematology.
[72] D. Loukopoulos,et al. Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. , 1995, Chest.
[73] P. Toutouzas,et al. Myocarditis in β-Thalassemia Major A Cause of Heart Failure , 1995 .
[74] F. Cerutti,et al. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. , 1995, Metabolism: clinical and experimental.
[75] P. Toutouzas,et al. Myocarditis in beta-thalassemia major. A cause of heart failure. , 1995, Circulation.
[76] P. van Eyken,et al. Iron concentration and distribution in the newborn liver. , 2008, Liver.
[77] A. Hoffbrand,et al. Deferiprone‐associated myelotoxicity , 1994, European journal of haematology.
[78] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[79] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[80] G. Koren,et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. , 1994, Blood.
[81] P. Dobbin,et al. Synthesis, Physicochemical Properties, and Biological Evaluation of N- Substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with Clinical Potential. , 1994 .
[82] R. Abeysinghe,et al. Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. , 1994, Advances in experimental medicine and biology.
[83] R. Hider,et al. Iron chelator design. , 1994, Advances in experimental medicine and biology.
[84] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[85] S. Menahem,et al. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. , 1993, Australian and New Zealand journal of medicine.
[86] J. Porter,et al. Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools , 1993, British journal of haematology.
[87] G. Brittenham,et al. Contrasting interspecies efficacy and toxicology of 1, 2 ‐diethy 1–3 ‐hydroxypyridin‐4‐one, CP9 4, relates to differing metabolism of the iron chelating site , 1993, British journal of haematology.
[88] R. Chatterjee,et al. Prospective study of the hypothalamic‐pituitary axis in thalassaemic patients who developed secondary amenorrhoea , 1993, Clinical endocrinology.
[89] D. van der Helm,et al. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. , 1993, Journal of medicinal chemistry.
[90] R. Abeysinghe,et al. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[91] D. Templeton,et al. Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. , 1993, The Journal of laboratory and clinical medicine.
[92] P. Bentley,et al. Toxicity of oral iron chelator L1 , 1993, The Lancet.
[93] L. Gullo,et al. Morphologic and Functional Evaluation of the Exocrine Pancreas in β‐Thalassemia Major , 1993, Pancreas.
[94] R. Abeysinghe,et al. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis. , 1993, Experimental hematology.
[95] R. Puniyani,et al. Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.
[96] R. Hider,et al. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. , 1992, Cancer research.
[97] A. Hoffbrand,et al. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. , 1992, Blood.
[98] I. Adamson,et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning , 1992, The Lancet.
[99] M. Freedman,et al. Growth failure and bony changes induced by deferoxamine. , 1992, The American journal of pediatric hematology/oncology.
[100] G. Lescoat,et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. , 1992, Journal of hepatology.
[101] G. Koren,et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. , 1992, Blood.
[102] G. Koren,et al. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. , 1991, International journal of hematology.
[103] S. Singhal,et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 , 1991, The Lancet.
[104] G. Koren,et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients , 1990, The Lancet.
[105] G. Kontoghiorghes,et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one , 1990, Clinical pharmacology and therapeutics.
[106] R. Hider,et al. Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids. , 1990, Analytical biochemistry.
[107] M. Freedman,et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. , 1990, American journal of diseases of children.
[108] B. Alter. Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation , 1990, The Lancet.
[109] D. Porcelli,et al. Hypothyroidism in patients with thalassemia syndromes. , 1990, Acta haematologica.
[110] J. Hazell,et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage , 1989, British journal of haematology.
[111] P. Veys,et al. AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIAL , 1989, The Lancet.
[112] A. Piga,et al. SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.
[113] E. Huehns,et al. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. , 1988, Blood.
[114] F. Cucca,et al. Deferoxamine-induced growth retardation in patients with thalassemia major. , 1988, The Journal of pediatrics.
[115] L. Luzzatto,et al. HIGH‐DOSE DESFERRIOXAMINE AS A CAUSE OF GROWTH FAILURE IN THALASSEMIC PATIENTS , 1988, European journal of haematology.
[116] G. Brittenham,et al. The effect of erythroid hyperplasia on iron balance. , 1988, Blood.
[117] C. Sklar,et al. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. , 1987, American journal of diseases of children.
[118] E. Chew,et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.
[119] Margot J. Taylor,et al. Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions , 1986 .
[120] R. Sherman,et al. Thrombocytopenia associated with intravenous desferrioxamine. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[121] J. Lunec,et al. Cerebral and ocular toxicity induced by desferrioxamine. , 1985, The Quarterly journal of medicine.
[122] S. Colan,et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.
[123] R. Robins-Browne,et al. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica , 1985, Infection and immunity.
[124] R. Dick,et al. Liver biopsy today. The Royal Free Hospital experience. , 1985, Journal of hepatology.
[125] G. Arden,et al. Ocular changes in patients undergoing long-term desferrioxamine treatment. , 1984, The British journal of ophthalmology.
[126] A. Piga,et al. Cirrhosis associated with multiple transfusions in thalassaemia. , 1984, Archives of disease in childhood.
[127] J. Bousquet,et al. RAPID DESENSITISATION FOR DESFERRIOXAMINE ANAPHYLACTOID REACTIONS , 1983, The Lancet.
[128] G. Arden,et al. OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.
[129] B. Bacon,et al. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. , 1983, The Journal of clinical investigation.
[130] J. Tripp,et al. Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.
[131] M. Pippard,et al. Ferrioxamine excretion in iron-loaded man. , 1982, Blood.
[132] J. Leonard,et al. Continuous RBC transfusions in a patient with sickle cell disease. , 1982, Archives of internal medicine.
[133] L. Rosenwasser,et al. RAPID DESENSITISATION FOR DESFERRIOXAMINE ANAPHYLACTIC REACTION , 1981, The Lancet.
[134] D. Weatherall,et al. IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA , 1979, The Lancet.
[135] A. Jacobs,et al. Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects , 1979, British journal of haematology.
[136] M. Skolnick,et al. Hereditary hemochromatosis. Phenotypic expression of the disease. , 1979, The New England journal of medicine.
[137] E. Rachmilewitz,et al. Mechanism of Desferrioxamine‐Induced Iron Excretion in Thalassaemia , 1979, British journal of haematology.
[138] D. Weatherall,et al. Iron absorption and loading in beta-thalassaemia intermedia. , 1979, Lancet.
[139] E. Rachmilewitz,et al. Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.
[140] A. Cerami,et al. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization. , 1978, The Journal of laboratory and clinical medicine.
[141] D. Weatherall,et al. PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIA , 1978, The Lancet.
[142] W. Anderson,et al. Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .
[143] A. Hoffbrand,et al. SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD , 1976, The Lancet.
[144] H. B. Neustein,et al. The liver in thalassaemia major: ultrastructural observations. , 1976, Ciba Foundation symposium.
[145] D. Flynn,et al. Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress , 1974, British medical journal.
[146] W. Roberts,et al. Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.
[147] J. B. Clegg,et al. The thalassaemia syndromes , 1965 .
[148] J. Wyatt,et al. The effect of long survival on the pathology of thalassaemia major. , 1961, The Journal of pathology and bacteriology.
[149] M. Margolies,et al. Liver disease in sickle cell anemia; a correlation of clinical, biochemical, histologic and histochemical observations. , 1955, The American journal of medicine.
[150] A. Frumin,et al. Exogenous hemochromatosis in sickle cell anemia. , 1953, Gastroenterology.
[151] C. Conley,et al. [The liver in sickle cell anemia]. , 1953, Bulletin of the Johns Hopkins Hospital.
[152] L. W. Diggs,et al. PATHOLOGY OF SICKLE CELL ANEMIA , 1934 .